Theranova versus FX80: The impact on anemia management in hemodialysis

Int J Artif Organs. 2024 Apr;47(4):260-268. doi: 10.1177/03913988241236736. Epub 2024 Mar 8.


Background: Middle uremic toxins (MUTs) can cause anemia and erythropoietin hyporesponsiveness. Theranova dialyzers may improve anemia management by removing MUTs. Hence, the impact of Theranova dialyzers on erythropoietin responsiveness was studied.

Methods: This exploratory single-center prospective observational study, encompassing 50 patients undergoing dialysis with either the Theranova-400 or FX80 membrane for 6 months, involved monthly tracking of hemoglobin levels, weight-adjusted erythropoiesis-stimulating agent (w-ESA) dosing, and erythropoietin resistance index (ERI), with ESA treatment decisions guided by a proprietary algorithm.

Results: The groups were similar in terms of demographics and baseline laboratory test results. The median hemoglobin levels, w-ESA and ERI, were found to be similar between FX80 and Theranova-400 groups at both baseline (11.06 vs 10.57, p = 0.808; 92.3 vs 105.2, p = 0.838; 8.1 vs 10.48, p = 0.876) and the end of the study (11.43 vs 11.03, p = 0.076; 48.7 vs 71.5; 4.48 vs 6.41, p = 0.310), respectively. There was a trend toward lower w-ESA and ERI at the end of the study compared to baseline in both groups, but the difference was non-significant.

Conclusions: Based on this study of 50 patients undergoing high-flux dialysis with near-target hemoglobin levels, switching to Theranova 400 dialyzers compared to FX80 dialyzers did not show statistically significant differences in maintaining hemoglobin levels, reducing ESA dose, or lowering ERI. The non-randomized design and small sample size limit the study's power to detect true differences. Larger, randomized trials are needed to confirm findings and definitively assess Theranova 400's benefits.

Keywords: Theranova (MCO dialyzer); anemia; erythropoiesis stimulating agents (ESA); erythropoietin resistance index (ERI); hemodialysis.

Publication types

  • Observational Study
  • Comparative Study

MeSH terms

  • Adult
  • Aged
  • Anemia* / blood
  • Anemia* / diagnosis
  • Anemia* / drug therapy
  • Anemia* / etiology
  • Anemia* / therapy
  • Erythropoietin / therapeutic use
  • Female
  • Hematinics* / administration & dosage
  • Hematinics* / therapeutic use
  • Hemoglobins* / metabolism
  • Humans
  • Male
  • Membranes, Artificial
  • Middle Aged
  • Prospective Studies
  • Renal Dialysis* / adverse effects
  • Treatment Outcome


  • Hematinics
  • Hemoglobins
  • Erythropoietin
  • Membranes, Artificial